These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9694951)

  • 1. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys.
    Gobburu JV; Tenhoor C; Rogge MC; Frazier DE; Thomas D; Benjamin C; Hess DM; Jusko WJ
    J Pharmacol Exp Ther; 1998 Aug; 286(2):925-30. PubMed ID: 9694951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
    Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The contribution of Fc effector mechanisms in the efficacy of anti-CD154 immunotherapy depends on the nature of the immune challenge.
    Ferrant JL; Benjamin CD; Cutler AH; Kalled SL; Hsu YM; Garber EA; Hess DM; Shapiro RI; Kenyon NS; Harlan DM; Kirk AD; Burkly LC; Taylor FR
    Int Immunol; 2004 Nov; 16(11):1583-94. PubMed ID: 15466914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.
    Zia-Amirhosseini P; Minthorn E; Benincosa LJ; Hart TK; Hottenstein CS; Tobia LA; Davis CB
    J Pharmacol Exp Ther; 1999 Dec; 291(3):1060-7. PubMed ID: 10565825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The application of target information and preclinical pharmacokinetic/pharmacodynamic modeling in predicting clinical doses of a Dickkopf-1 antibody for osteoporosis.
    Betts AM; Clark TH; Yang J; Treadway JL; Li M; Giovanelli MA; Abdiche Y; Stone DM; Paralkar VM
    J Pharmacol Exp Ther; 2010 Apr; 333(1):2-13. PubMed ID: 20089807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration.
    Gaudreault J; Fei D; Rusit J; Suboc P; Shiu V
    Invest Ophthalmol Vis Sci; 2005 Feb; 46(2):726-33. PubMed ID: 15671306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical pharmacokinetics of MFGR1877A, a human monoclonal antibody to FGFR3, and prediction of its efficacious clinical dose for the treatment of t(4;14)-positive multiple myeloma.
    Kamath AV; Lu D; Gupta P; Jin D; Xin Y; Brady A; Stephan JP; Li H; Tien J; Qing J; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1071-8. PubMed ID: 22203368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
    Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
    Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus.
    Davis JC; Totoritis MC; Rosenberg J; Sklenar TA; Wofsy D
    J Rheumatol; 2001 Jan; 28(1):95-101. PubMed ID: 11196549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys.
    Imai A; Suzuki T; Sugitani A; Itoh T; Ueki S; Aoyagi T; Yamashita K; Taniguchi M; Takahashi N; Miura T; Shimamura T; Furukawa H; Todo S
    Transplantation; 2007 Oct; 84(8):1020-8. PubMed ID: 17989608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors.
    Ewenstein BM; Hoots WK; Lusher JM; DiMichele D; White GC; Adelman B; Nadeau K
    Haematologica; 2000 Oct; 85(10 Suppl):35-9. PubMed ID: 11187868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
    Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDP7657, an anti-CD40L antibody lacking an Fc domain, inhibits CD40L-dependent immune responses without thrombotic complications: an in vivo study.
    Shock A; Burkly L; Wakefield I; Peters C; Garber E; Ferrant J; Taylor FR; Su L; Hsu YM; Hutto D; Amirkhosravi A; Meyer T; Francis J; Malcolm S; Robinson M; Brown D; Shaw S; Foulkes R; Lawson A; Harari O; Bourne T; Maloney A; Weir N
    Arthritis Res Ther; 2015 Sep; 17(1):234. PubMed ID: 26335795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloimmunity in primate heart recipients with CD154 blockade: evidence for alternative costimulation mechanisms.
    Azimzadeh AM; Pfeiffer S; Wu G; Schröder C; Zorn GL; Kelishadi SS; Ozkaynak E; Kehry M; Atkinson JB; Miller GG; Pierson RN
    Transplantation; 2006 Jan; 81(2):255-64. PubMed ID: 16436970
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical dose.
    Kamath AV; Lu D; Gupta P; Jin D; Xiang H; Wong A; Leddy C; Crocker L; Schaefer G; Sliwkowski MX; Damico-Beyer LA
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):1063-9. PubMed ID: 22203367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonist anti-human CD40 antibody inhibits germinal center formation in cynomolgus monkeys.
    de Vos AF; Melief MJ; van Riel D; Boon L; van Eijk M; de Boer M; Laman JD
    Eur J Immunol; 2004 Dec; 34(12):3446-55. PubMed ID: 15517614
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer.
    Qian J; Burkly LC; Smith EP; Ferrant JL; Hoyer LW; Scott DW; Haudenschild CC
    Eur J Immunol; 2000 Sep; 30(9):2548-54. PubMed ID: 11009088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apoptotic donor leukocytes limit mixed-chimerism induced by CD40-CD154 blockade in allogeneic bone marrow transplantation.
    Li JM; Gorechlad J; Larsen CP; Waller EK
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1239-49. PubMed ID: 17162205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of ASKP1240, a fully human anti-CD40 antibody, in normal and renal transplanted Cynomolgus monkeys.
    Ma A; Dun H; Song L; Hu Y; Zeng L; Bai J; Zhang G; Kinugasa F; Miyao Y; Sakuma S; Okimura K; Kasai N; Daloze P; Chen H
    Transplantation; 2014 Feb; 97(4):397-404. PubMed ID: 24389907
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiple-dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects.
    Kovarik JM; Schmouder R; Barilla D; Riviere GJ; Wang Y; Hunt T
    J Clin Pharmacol; 2004 May; 44(5):532-7. PubMed ID: 15102874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.